AstraZeneca PLC (AZN) operating KPIs

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30

$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca brilinta / Brilique (ticagrelor) — Worldwide product sales ($M) ($M)

Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables

Quarterly Annual

Latest, Q2 2026

Period ended Jun 30, 2026

Change on a year earlier

-62.8%

215 in Q2 2025

History

42 quarters

Since Q1 2016

Sources

Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Brilinta / Brilique (ticagrelor) — Worldwide product sales ($M) ($M)	Year on year	Source
Q2 2026	Jun 30, 2026	80	-62.8%	Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026	Mar 31, 2026	105	-65.6%	Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025	Dec 31, 2025	158	-53.7%	Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025	Sep 30, 2025	146	-55.4%	Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025	Jun 30, 2025	215	-37.1%	Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025	Mar 31, 2025	305	-5.6%	Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024	Dec 31, 2024	341	+3.6%	Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024	Sep 30, 2024	327	-1.2%	Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024	Jun 30, 2024	342	+3.3%	Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024	Mar 31, 2024	323	-3.3%	Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023	Dec 31, 2023	329	-4.6%	Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023	Sep 30, 2023	331	-2.1%	Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023	Jun 30, 2023	331	-5.4%	Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023	Mar 31, 2023	334	+2.8%	Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022	Dec 31, 2022	345	-0.9%	Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022	Sep 30, 2022	338	-9.9%	Form 6-K FY2022Q3 Earnings Release ↗
Q2 2022	Jun 30, 2022	350	-6.7%	Form 6-K FY2022Q2 Earnings Release ↗
Q1 2022	Mar 31, 2022	325	-13.1%	Form 6-K FY2022Q1 Earnings Release ↗
Q4 2021	Dec 31, 2021	348	-4.1%	Form 6-K FY2021Q4 Earnings Release ↗
Q3 2021	Sep 30, 2021	375	-2.6%	Form 6-K FY2021Q3 Earnings Release ↗
Q2 2021	Jun 30, 2021	375	-14.2%	Form 6-K FY2021Q2 Earnings Release ↗
Q1 2021	Mar 31, 2021	374	-8.3%	Form 6-K FY2021Q1 Earnings Release ↗
Q4 2020	Dec 31, 2020	363	-15.2%	Form 6-K FY2020Q4 Earnings Release ↗
Q3 2020	Sep 30, 2020	385	-7.5%	Form 6-K (filed 2021-07-30) ↗
Q2 2020	Jun 30, 2020	437	+12.3%	Form 6-K/A (filed 2020-07-31) ↗
Q1 2020	Mar 31, 2020	408	+17.2%	Form 6-K/A (filed 2020-07-31) ↗
Q4 2019	Dec 31, 2019	428	+13.8%	Form 6-K/A (filed 2020-07-31) ↗
Q3 2019	Sep 30, 2019	416	+23.8%	Form 6-K/A (filed 2020-07-31) ↗
Q2 2019	Jun 30, 2019	389	+23.1%	Form 6-K (filed 2019-07-25) ↗
Q1 2019	Mar 31, 2019	348	+18.8%	Form 6-K (filed 2019-07-25) ↗
Q4 2018	Dec 31, 2018	376	+25.8%	Form 6-K (filed 2019-07-25) ↗
Q3 2018	Sep 30, 2018	336	+18.3%	Form 6-K (filed 2019-07-25) ↗
Q2 2018	Jun 30, 2018	316	+16.2%	Form 6-K (filed 2018-07-26) ↗
Q1 2018	Mar 31, 2018	293	+30.8%	Form 6-K (filed 2018-07-26) ↗
Q4 2017	Dec 31, 2017	299	+26.7%	Form 6-K (filed 2018-07-26) ↗
Q3 2017	Sep 30, 2017	284	+36.5%	Form 6-K (filed 2018-07-26) ↗
Q2 2017	Jun 30, 2017	272	+27.1%	Form 6-K (filed 2018-07-26) ↗
Q1 2017	Mar 31, 2017	224	+23.8%	Form 6-K (filed 2018-07-26) ↗
Q4 2016	Dec 31, 2016	236	–	Form 6-K (filed 2018-07-26) ↗
Q3 2016	Sep 30, 2016	208	–	Form 6-K (filed 2018-07-26) ↗
Q2 2016	Jun 30, 2016	214	–	Form 6-K (filed 2018-07-26) ↗
Q1 2016	Mar 31, 2016	181	–	Form 6-K (filed 2018-07-26) ↗

Breakdown

What makes up brilinta / brilique (ticagrelor) — worldwide product sales ($m)

Cite this data

StockData. (2026). AstraZeneca Brilinta / Brilique (ticagrelor) — Worldwide product sales ($M) ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_brilinta_world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.